Literature DB >> 21881509

Pulmonary exacerbations in cystic fibrosis.

Antine E Stenbit1, Patrick A Flume.   

Abstract

PURPOSE OF REVIEW: The chronic infection and inflammation of cystic fibrosis (CF) lung disease causes a progressive decline of lung function resulting in daily symptoms such as cough and sputum production. There are intermittent episodes of acute worsening of symptoms, more commonly referred to as pulmonary exacerbations. Despite this being a common event, there is still no standardized definition of an exacerbation. A recent set of guidelines from the CF Foundation Pulmonary Therapies Committee on the treatment of exacerbations noted the paucity of data supporting commonly used therapies. This review describes our current understanding of pulmonary exacerbations and the therapies used to treat them. RECENT
FINDINGS: The treatment of an exacerbation is intended to resolve the worsened symptoms and to restore the lung function that is commonly lost in the acute presentation. A most striking finding is the observation that for many patients there is no restoration of lung function, suggesting we either need better therapies to prevent exacerbations or better treatment of exacerbations.
SUMMARY: We have established recommendations on specific treatment of a pulmonary exacerbation and have outlined the areas where we need better information on appropriate therapies. Once we have a standardized definition of an exacerbation, we can proceed with clinical trials of therapies specific for its treatment.
© 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2011        PMID: 21881509     DOI: 10.1097/MCP.0b013e32834b8c04

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  41 in total

Review 1.  Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

Authors:  George A O'Toole
Journal:  J Bacteriol       Date:  2018-01-24       Impact factor: 3.490

Review 2.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

3.  Risk factors for totally implantable venous access device-associated complications in cystic fibrosis.

Authors:  C McCarthy; O O'Carroll; M E O'Brien; T McEnery; A Franciosi; C Gunaratnam; N G McElvaney
Journal:  Ir J Med Sci       Date:  2017-08-15       Impact factor: 1.568

4.  Development of an airway mucus defect in the cystic fibrosis rat.

Authors:  Susan E Birket; Joy M Davis; Courtney M Fernandez; Katherine L Tuggle; Ashley M Oden; Kengyeh K Chu; Guillermo J Tearney; Michelle V Fanucchi; Eric J Sorscher; Steven M Rowe
Journal:  JCI Insight       Date:  2018-01-11

Review 5.  Antibiotic and anti-inflammatory therapies for cystic fibrosis.

Authors:  James F Chmiel; Michael W Konstan; J Stuart Elborn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

6.  What is hepcidin telling us about the natural history of cystic fibrosis?

Authors:  A H Gifford
Journal:  J Cyst Fibros       Date:  2014-04-30       Impact factor: 5.482

7.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

8.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

9.  Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.

Authors:  Jeffrey S Wagener; Lawrence Rasouliyan; Donald R VanDevanter; David J Pasta; Warren E Regelmann; Wayne J Morgan; Michael W Konstan
Journal:  Pediatr Pulmonol       Date:  2012-08-08

Review 10.  The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease.

Authors:  David N O'Dwyer; Robert P Dickson; Bethany B Moore
Journal:  J Immunol       Date:  2016-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.